MedyMatch Reveals Artificial Intelligence Deep Vision Intracranial Bleed Detection Technology

TEL AVIV, Israel, November 22, 2016 /PRNewswire/ --

MedyMatch Technology Ltd., ("MedyMatch") the deep learning and artificial intelligence company, announced today that after several years of extensive research and development, it has achieved a major milestone in the availability, for research, of an artificial intelligence based technology that can help detect the presence of intracranial hemorrhage or brain bleed which can occur in cases of brain trauma and stroke.  Subtle bleeds are difficult to detect and if misinterpreted or missed by a physician can lead to serious patient injury and even death.

Per the American Heart Association and American Stroke Association (AHA/ASA), stroke is the fourth leading cause of death and one of the top causes of preventable disability in the United States. Affecting 4% of U.S. adults, it is forecasted that by 2030 there will be approximately 3.4 million stroke victims annually in the U.S., costing the healthcare system $240 Billion on an annual basis.

It is anticipated that this new technology will come to the marketplace in several forms: a patient specific computer assisted detection ("CAD") tool used by physicians in the emergency room to assist in the detection of intracranial bleeds; a prioritization algorithm operating within a PACS or on a CT to help prioritize cases based on the potential presence of a bleed; and as a tool to provide insights into populations to proactively identify bleed cases.

Deployment will be customer driven as either a cloud or on-premises based solution, with near zero foot-print and seamless integration into a hospital enterprise, integrating smoothly into clinical workflow.  

"The generalized 3D deep vision platform approach has the promise to tackle many diseases.  We have developed the capability to consider the full richness of medical imaging along with any other patient data," said Gene Saragnese, Chairman & CEO of MedyMatch. "Our platform and A.I. approach will facilitate rapid decision support development, clinical discovery and propel MedyMatch into adjacent decision support opportunities."

It is envisioned that MedyMatch's technology will assist physicians and not replace them, essentially providing a virtual "second set of eyes" to help physicians assess radiology images as accurately as possible.    

"Consideration of the whole patient differentiates MedyMatch from traditional CAD applications," said Dr. Jacob Cohen, Chief Technical Officer of MedyMatch. "While traditional CADs strictly focus on pixel data, MedyMatch's technology applies deep learning and computer vision ("Deep Vision") to interpret the full richness of the 3D imaging data together with the patient's Electronic Medical Record ("EMR"), allowing the system to consider the 'whole' patient."

MedyMatch's goal is to harness clinical understanding in conjunction with computer vision and deep learning to provide real time artificial intelligence-based clinical decision support to physicians in the emergency room.  To accomplish this, MedyMatch considers all the multidimensional patient data; raw imaging concurrently with other relevant patient data at the leading edge of machine learning technologies.

About MedyMatch Technology, Ltd. 

MedyMatch utilizes advanced cognitive analytics and artificial intelligence to deliver real-time decision support tools to improve clinical outcomes in acute medical scenarios. The foundation of clinical discovery and value creation lies in the deep clinical understanding of how to utilize the right data (electronic medical record, medical imaging, and genomic data).  The MedyMatch team of artificial intelligence, machine learning, deep learning algorithms experts along with its medical and science advisory boards are achieving breakthroughs in standards of cost and care. To learn more, please visit http://www.medymatch.com. Join the conversation at #medymatch and follow us on twitter at @medymatch. Caution: Limited by Federal (or United States) law to investigational use.

For More Information Contact:
Michael Rosenberg
Corporate Development Officer & CFO
[email protected]
+972-52-323-7334

SOURCE MedyMatch Technology, Ltd.